PrEP有效性：HUANG等[4]针对MSM的荟萃分析提示，PrEP能够显著降低该人群的HIV新发感染率 80%以上， 校...
大量临床试验证明：PrEP 能够有效预防HIV感染。研究表明¹ ²，在按时按量服药的情况下，PrEP能够降低9...
Sexually transmitted infection (STI) clinics are used by large numbers of individuals at substantial risk of HIV, and their focus on sexual health makes PrEP easy to integrate in the provider-patient discussion. HIV testing, risk assessments, and discussions about HIV prevention are already happening...
2012年七月美国食品药管理局(Food and Drug Association; FDA)正式核准tenofovir + emtricitabine(TDF/FTC, Truvada特鲁瓦达)成为HIV暴露前预防性服药的首选药物。2011年美国疾病管制及预防中心(The Centers for Disease Control and Prevention in Untied States)首先针对男男性行为者,制定HIV暴露前预防性服药暂时性的使...
Donnell教授:这些新型长效生物制剂有望真正改变预防工作的格局,使我们能够找到解决临床实施问题的方法,进而使所有具有感染HIV风险的人群能够获得长效抗反转录病毒治疗,并在没有感染HIV风险的情况下生活。我认为长效预防产品确实有潜力做到这一点。 IDF: In what ways might these new biologics transform HIV prevention st...
PrEP, a drug used to reduce the risk ofHIVtransmission, will be made “routinely available across England,” according to astatementfrom the Department of Health published today (March 15). The provision of the drug is due to start later this year, and comes at the e...
CROPrEP是一项真实世界研究,在中国四个城市(沈阳、北京、深圳和重庆)招募了未感染HIV的高风险MSM,根据个人喜好选择每日服药或按需服药的PrEP方案,在随访的第1、3、6、9和12个月时分别接受临床评估、实验室检测,以及线上问卷形式的性行为...
You are an injection drug user. You have other reasons to think you are at risk for HIV. Today you have options when it comes to taking PrEP. The medicine comes as two different pills and an injection. It's important to talk to your doctor about whether you should go on PrEP, and ...
近日,美国食品药品监督管理局(FDA)批准ViiV Healthcare研发的长效注射针剂卡博特韦(cabotegravir,英文商品名Apretude),用于体重≥35公斤(77磅)的高风险成人和青少年进行HIV暴露前预防(PrEP)。这是全球首款无需每日服药的长效PrEP方案。 PrEP的重大突破 HIV...
近日,美国食品药品监督管理局(FDA)批准ViiV Healthcare研发的长效注射针剂卡博特韦(cabotegravir,英文商品名Apretude),用于体重≥35公斤(77磅)的高风险成人和青少年进行HIV暴露前预防(PrEP)。这是全球首款无需每日服药的长效PrEP方案。 图片 PrEP的重大突破 ...